Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 1 Sell Rating(s), 4 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $59.87 (17.20% upside)

Current Analysts' Coverage Summary for Ligand Pharmaceuticals (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetDetailsShare
7/22/2014Empire Asset ManagementInitiated CoverageSell$16.00ViewTweet This Rating  Share This Rating on StockTwits
6/25/2014Roth CapitalInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
4/28/2014Ned Davis ResearchUpgradeSell -> NeutralViewTweet This Rating  Share This Rating on StockTwits
3/24/2014Brinson PatrickInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
2/24/2014Summer StreetBoost Price TargetBuy$78.00 -> $91.00ViewTweet This Rating  Share This Rating on StockTwits
2/21/2014ZacksDowngradeOutperform -> Neutral$81.20ViewTweet This Rating  Share This Rating on StockTwits
2/13/2014TheStreetUpgradeHold -> BuyViewTweet This Rating  Share This Rating on StockTwits
2/10/2014MLV & Co Boost Price TargetBuy$82.00ViewTweet This Rating  Share This Rating on StockTwits
12/10/2013Cantor FitzgeraldReiterated RatingHold$43.00 -> $44.00ViewTweet This Rating  Share This Rating on StockTwits
10/31/2013Brean CapitalDowngradeBuy -> Hold$45.00ViewTweet This Rating  Share This Rating on StockTwits
6/20/2013Craig HallumInitiated CoverageBuy$60.00ViewTweet This Rating  Share This Rating on StockTwits
8/14/2012Griffin SecuritiesReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2012 forward)